001010513 001__ 1010513
001010513 005__ 20231027114413.0
001010513 0247_ $$2doi$$a10.1667/RADE-22-00207.1
001010513 0247_ $$2ISSN$$a0033-7587
001010513 0247_ $$2ISSN$$a1938-5404
001010513 0247_ $$2datacite_doi$$a10.34734/FZJ-2023-03096
001010513 0247_ $$2pmid$$a37310880
001010513 0247_ $$2WOS$$aWOS:001004143500002
001010513 037__ $$aFZJ-2023-03096
001010513 041__ $$aEnglish
001010513 082__ $$a530
001010513 1001_ $$0P:(DE-HGF)0$$aPort, M.$$b0
001010513 245__ $$aRENEB Inter-Laboratory Comparison 2021: Inter-Assay Comparison of Eight Dosimetry Assays
001010513 260__ $$aGreat Falls, Va.$$bRadiation Research Society$$c2023
001010513 3367_ $$2DRIVER$$aarticle
001010513 3367_ $$2DataCite$$aOutput Types/Journal article
001010513 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1692363442_8449
001010513 3367_ $$2BibTeX$$aARTICLE
001010513 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001010513 3367_ $$00$$2EndNote$$aJournal Article
001010513 520__ $$aTools for radiation exposure reconstruction are required to support the medical management of radiation victims in radiological or nuclear incidents. Different biological and physical dosimetry assays can be used for various exposure scenarios to estimate the dose of ionizing radiation a person has absorbed. Regular validation of the techniques through inter-laboratory comparisons (ILC) is essential to guarantee high quality results. In the current RENEB inter-laboratory comparison, the performance quality of established cytogenetic assays [dicentric chromosome assay (DCA), cytokinesis-block micronucleus assay (CBMN), stable chromosomal translocation assay (FISH) and premature chromosome condensation assay (PCC)] was tested in comparison to molecular biological assays [gamma-H2AX foci (gH2AX), gene expression (GE)] and physical dosimetry-based assays [electron paramagnetic resonance (EPR), optically or thermally stimulated luminescence (LUM)]. Three blinded coded samples (e.g., blood, enamel or mobiles) were exposed to 0, 1.2 or 3.5 Gy X-ray reference doses (240 kVp, 1 Gy/min). These doses roughly correspond to clinically relevant groups of unexposed to low exposed (0-1 Gy), moderately exposed (1-2 Gy, no severe acute health effects expected) and highly exposed individuals (>2 Gy, requiring early intensive medical care). In the frame of the current RENEB inter-laboratory comparison, samples were sent to 86 specialized teams in 46 organizations from 27 nations for dose estimation and identification of three clinically relevant groups. The time for sending early crude reports and more precise reports was documented for each laboratory and assay where possible. The quality of dose estimates was analyzed with three different levels of granularity, 1. by calculating the frequency of correctly reported clinically relevant dose categories, 2. by determining the number of dose estimates within the uncertainty intervals recommended for triage dosimetry (±0.5 Gy or ±1.0 Gy for doses <2.5 Gy or >2.5 Gy), and 3. by calculating the absolute difference (AD) of estimated doses relative to the reference doses. In total, 554 dose estimates were submitted within the 6-week period given before the exercise was closed. For samples processed with the highest priority, earliest dose estimates/categories were reported within 5-10 h of receipt for GE, gH2AX, LUM, EPR, 2-3 days for DCA, CBMN and within 6-7 days for the FISH assay. For the unirradiated control sample, the categorization in the correct clinically relevant group (0-1 Gy) as well as the allocation to the triage uncertainty interval was, with the exception of a few outliers, successfully performed for all assays. For the 3.5 Gy sample the percentage of correct classifications to the clinically relevant group (≥2 Gy) was between 89-100% for all assays, with the exception of gH2AX. For the 1.2 Gy sample, an exact allocation to the clinically relevant group was more difficult and 0-50% or 0-48% of the estimates were wrongly classified into the lowest or highest dose categories, respectively. For the irradiated samples, the correct allocation to the triage uncertainty intervals varied considerably between assays for the 1.2 Gy (29-76%) and 3.5 Gy (17-100%) samples. While a systematic shift towards higher doses was observed for the cytogenetic-based assays, extreme outliers exceeding the reference doses 2-6 fold were observed for EPR, FISH and GE assays. These outliers were related to a particular material examined (tooth enamel for EPR assay, reported as kerma in enamel, but when converted into the proper quantity, i.e. to kerma in air, expected dose estimates could be recalculated in most cases), the level of experience of the teams (FISH) and methodological uncertainties (GE). This was the first RENEB ILC where everything, from blood sampling to irradiation and shipment of the samples, was organized and realized at the same institution, for several biological and physical retrospective dosimetry assays. Almost all assays appeared comparably applicable for the identification of unexposed and highly exposed individuals and the allocation of medical relevant groups, with the latter requiring medical support for the acute radiation scenario simulated in this exercise. However, extreme outliers or a systematic shift of dose estimates have been observed for some assays. Possible reasons will be discussed in the assay specific papers of this special issue. In summary, this ILC clearly demonstrates the need to conduct regular exercises to identify research needs, but also to identify technical problems and to optimize the design of future ILCs
001010513 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
001010513 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001010513 65027 $$0V:(DE-MLZ)SciArea-160$$2V:(DE-HGF)$$aBiology$$x0
001010513 7001_ $$aBarquinero, J-F.$$b1
001010513 7001_ $$0P:(DE-HGF)0$$aEndesfelder, D.$$b2
001010513 7001_ $$0P:(DE-HGF)0$$aMoquet, J.$$b3
001010513 7001_ $$0P:(DE-HGF)0$$aOestreicher, U.$$b4
001010513 7001_ $$0P:(DE-HGF)0$$aTerzoudi, G.$$b5
001010513 7001_ $$0P:(DE-HGF)0$$aTrompier, F.$$b6
001010513 7001_ $$0P:(DE-HGF)0$$aVral, A.$$b7
001010513 7001_ $$0P:(DE-HGF)0$$aAbe, Y.$$b8
001010513 7001_ $$0P:(DE-HGF)0$$aAinsbury, L.$$b9
001010513 7001_ $$0P:(DE-HGF)0$$aAlkebsi, L.$$b10
001010513 7001_ $$0P:(DE-HGF)0$$aAmundson, S. A.$$b11
001010513 7001_ $$0P:(DE-HGF)0$$aBadie, C.$$b12
001010513 7001_ $$0P:(DE-HGF)0$$aBaeyens, A.$$b13
001010513 7001_ $$0P:(DE-HGF)0$$aBalajee, A. S.$$b14
001010513 7001_ $$0P:(DE-HGF)0$$aBalázs, K.$$b15
001010513 7001_ $$0P:(DE-HGF)0$$aBarnard, S.$$b16
001010513 7001_ $$0P:(DE-HGF)0$$aBassinet, C.$$b17
001010513 7001_ $$0P:(DE-HGF)0$$aBeaton-Green, L. A.$$b18
001010513 7001_ $$0P:(DE-HGF)0$$aBeinke, C.$$b19
001010513 7001_ $$0P:(DE-HGF)0$$aBobyk, L.$$b20
001010513 7001_ $$0P:(DE-HGF)0$$aBrochard, P.$$b21
001010513 7001_ $$0P:(DE-HGF)0$$aCiesielski, B.$$b22
001010513 7001_ $$0P:(DE-HGF)0$$aCuceu, C.$$b23
001010513 7001_ $$0P:(DE-HGF)0$$aDischer, M.$$b24
001010513 7001_ $$0P:(DE-HGF)0$$aD,Oca, M. C.$$b25
001010513 7001_ $$0P:(DE-HGF)0$$aDomínguez, I.$$b26
001010513 7001_ $$0P:(DE-HGF)0$$aDoucha-Senf, S.$$b27
001010513 7001_ $$0P:(DE-HGF)0$$aDumitrescu, A.$$b28
001010513 7001_ $$0P:(DE-HGF)0$$aDuy, P. N.$$b29
001010513 7001_ $$0P:(DE-HGF)0$$aFinot, F.$$b30
001010513 7001_ $$0P:(DE-HGF)0$$aGarty, G.$$b31
001010513 7001_ $$0P:(DE-HGF)0$$aGhandhi, S. A.$$b32
001010513 7001_ $$0P:(DE-HGF)0$$aGregoire, E.$$b33
001010513 7001_ $$0P:(DE-HGF)0$$aGoh, V. S. T.$$b34
001010513 7001_ $$0P:(DE-HGF)0$$aGüçlü, I.$$b35
001010513 7001_ $$0P:(DE-HGF)0$$aHadjiiska, L.$$b36
001010513 7001_ $$0P:(DE-HGF)0$$aHargitai, R.$$b37
001010513 7001_ $$0P:(DE-HGF)0$$aHristova, R.$$b38
001010513 7001_ $$0P:(DE-HGF)0$$aIshii, K.$$b39
001010513 7001_ $$0P:(DE-HGF)0$$aKis, E.$$b40
001010513 7001_ $$0P:(DE-HGF)0$$aJuniewicz, M.$$b41
001010513 7001_ $$0P:(DE-Juel1)133469$$aKriehuber, R.$$b42$$ufzj
001010513 7001_ $$0P:(DE-HGF)0$$aLacombe, J.$$b43
001010513 7001_ $$0P:(DE-HGF)0$$aLee, Y.$$b44
001010513 7001_ $$0P:(DE-HGF)0$$aLopez Riego, M.$$b45
001010513 7001_ $$0P:(DE-HGF)0$$aLumniczky, K.$$b46
001010513 7001_ $$0P:(DE-HGF)0$$aMai, T. T.$$b47
001010513 7001_ $$0P:(DE-HGF)0$$aMaltar-Strmečki, N.$$b48
001010513 7001_ $$0P:(DE-HGF)0$$aMarrale, M.$$b49
001010513 7001_ $$0P:(DE-HGF)0$$aMartinez, J. S.$$b50
001010513 7001_ $$0P:(DE-HGF)0$$aMarciniak, A.$$b51
001010513 7001_ $$0P:(DE-HGF)0$$aMaznyk, N.$$b52
001010513 7001_ $$0P:(DE-HGF)0$$aMcKeever, S. W. S.$$b53
001010513 7001_ $$0P:(DE-HGF)0$$aMeher, P. K.$$b54
001010513 7001_ $$0P:(DE-HGF)0$$aMilanova, M.$$b55
001010513 7001_ $$0P:(DE-HGF)0$$aMiura, T.$$b56
001010513 7001_ $$0P:(DE-HGF)0$$aMonteiro Gil, O.$$b57
001010513 7001_ $$0P:(DE-HGF)0$$aMontoro, A.$$b58
001010513 7001_ $$0P:(DE-HGF)0$$aMoreno Domene, M.$$b59
001010513 7001_ $$0P:(DE-HGF)0$$aMrozik, A.$$b60
001010513 7001_ $$0P:(DE-HGF)0$$aNakayama, R.$$b61
001010513 7001_ $$0P:(DE-HGF)0$$aO'Brien, G.$$b62
001010513 7001_ $$0P:(DE-Juel1)133339$$aOskamp, D.$$b63$$ufzj
001010513 7001_ $$0P:(DE-HGF)0$$aOstheim, P.$$b64
001010513 7001_ $$0P:(DE-HGF)0$$aPajic, J.$$b65
001010513 7001_ $$0P:(DE-HGF)0$$aPastor, N.$$b66
001010513 7001_ $$0P:(DE-HGF)0$$aPatrono, C.$$b67
001010513 7001_ $$0P:(DE-HGF)0$$aPrieto Rodriguez, M. J.$$b68
001010513 7001_ $$0P:(DE-HGF)0$$aPujol-Canadell, M.$$b69
001010513 7001_ $$0P:(DE-HGF)0$$aRepin, M.$$b70
001010513 7001_ $$0P:(DE-HGF)0$$aRomanyukha, A.$$b71
001010513 7001_ $$0P:(DE-HGF)0$$aRößler, U.$$b72
001010513 7001_ $$0P:(DE-HGF)0$$aSabatier, L.$$b73
001010513 7001_ $$0P:(DE-HGF)0$$aSakai, A.$$b74
001010513 7001_ $$0P:(DE-HGF)0$$aScherthan, H.$$b75
001010513 7001_ $$0P:(DE-HGF)0$$aSchüle, S.$$b76
001010513 7001_ $$0P:(DE-HGF)0$$aSeong, K. M.$$b77
001010513 7001_ $$0P:(DE-HGF)0$$aSevriukova, O.$$b78
001010513 7001_ $$0P:(DE-HGF)0$$aSholom, S.$$b79
001010513 7001_ $$0P:(DE-HGF)0$$aSommer, S.$$b80
001010513 7001_ $$0P:(DE-HGF)0$$aSuto, Y.$$b81
001010513 7001_ $$0P:(DE-HGF)0$$aSypko, T.$$b82
001010513 7001_ $$0P:(DE-HGF)0$$aSzatmári, T.$$b83
001010513 7001_ $$0P:(DE-HGF)0$$aTakahashi-Sugai, M.$$b84
001010513 7001_ $$0P:(DE-HGF)0$$aTakebayashi, K.$$b85
001010513 7001_ $$0P:(DE-HGF)0$$aTesta, A.$$b86
001010513 7001_ $$0P:(DE-HGF)0$$aTestard, I.$$b87
001010513 7001_ $$0P:(DE-HGF)0$$aTichy, A. ii A.$$b88
001010513 7001_ $$0P:(DE-HGF)0$$aTriantopoulou, S.$$b89
001010513 7001_ $$0P:(DE-HGF)0$$aTsuyama, N.$$b90
001010513 7001_ $$0P:(DE-HGF)0$$aUnverricht-Yeboah, M.$$b91
001010513 7001_ $$0P:(DE-HGF)0$$aValente, M.$$b92
001010513 7001_ $$0P:(DE-HGF)0$$aVan Hoey, O.$$b93
001010513 7001_ $$0P:(DE-HGF)0$$aWilkins, R. C.$$b94
001010513 7001_ $$0P:(DE-HGF)0$$aWojcik, A.$$b95
001010513 7001_ $$0P:(DE-HGF)0$$aWojewodzka, M.$$b96
001010513 7001_ $$0P:(DE-HGF)0$$aYounghyun, Lee$$b97
001010513 7001_ $$0P:(DE-HGF)0$$aZafiropoulos, D.$$b98
001010513 7001_ $$0P:(DE-HGF)0$$aAbend, M.$$b99
001010513 773__ $$0PERI:(DE-600)2135113-2$$a10.1667/RADE-22-00207.1$$gVol. 199, no. 6$$n6$$p535-555$$tRadiation research$$v199$$x0033-7587$$y2023
001010513 8564_ $$uhttps://juser.fz-juelich.de/record/1010513/files/RADE-22-00207.1.pdf$$yOpenAccess
001010513 909CO $$ooai:juser.fz-juelich.de:1010513$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
001010513 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)133469$$aForschungszentrum Jülich$$b42$$kFZJ
001010513 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)133339$$aForschungszentrum Jülich$$b63$$kFZJ
001010513 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
001010513 9141_ $$y2023
001010513 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-11
001010513 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-11
001010513 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-11
001010513 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001010513 915__ $$0StatID:(DE-HGF)0430$$2StatID$$aNational-Konsortium$$d2023-10-25$$wger
001010513 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bRADIAT RES : 2022$$d2023-10-25
001010513 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
001010513 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
001010513 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
001010513 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-25
001010513 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
001010513 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-25
001010513 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-25
001010513 9201_ $$0I:(DE-Juel1)S-US-20090406$$kS-US$$lSicherheit und Strahlenschutz, Umgebungsüberwachung,Strahlenbiologie$$x0
001010513 980__ $$ajournal
001010513 980__ $$aVDB
001010513 980__ $$aUNRESTRICTED
001010513 980__ $$aI:(DE-Juel1)S-US-20090406
001010513 9801_ $$aFullTexts